Fever pitch: improving the management of febrile patients

EU-funded researchers are seeking to improve the diagnosis and management of patients with fever through the identification of new biomarkers that can differentiate between bacterial and viral infection. Once found, the biomarkers will be evaluated across different European healthcare models.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 6 June 2018  
Related theme(s) and subtheme(s)
Health & life sciencesBiotechnology  |  Medical research  |  Public health
Research policyHorizon 2020
Countries involved in the project described in the article
Austria  |  France  |  Germany  |  Greece  |  Latvia  |  Netherlands  |  Slovenia  |  Spain  |  Switzerland
Add to PDF "basket"

Fever pitch: improving the management of febrile patients

Image

© artem_goncharov #201868464, 2018. Source: fotolia.com

Febrile illness – the manifestation of a high fever – can be problematic for healthcare providers who, in their search to identify the cause, cannot always tell whether a patient is suffering from a bacterial or viral infection. Febrile patients are therefore often unnecessarily subjected to hospitalisation, invasive investigation and antibiotic treatment for a presumed bacterial infection when their fever is caused by a trivial, self-resolving viral infection.

The PERFORM project’s approach to improving diagnosis and the management of febrile patients is to combine clinical data and characterise clinical samples from European and African patients, building on previous EU-funded studies to develop Europe’s most comprehensive biobank to date.

This biobank will enable the project partners to identify candidate biomarkers to distinguish between bacterial and viral infection.

The biomarkers identified as the most accurate will then be tested and evaluated in patients suffering from febrile illness across different healthcare settings in the EU. Building on pilot data from previous studies, including healthcare provider and patient surveys, the results will be used to develop a management plan for febrile patients, which could be rolled out across Europe.

The management plan will include novel diagnostic tests that use clinical markers for febrile illness as well as guidelines for their application, with specific reference to children.

Project details

  • Project acronym: PERFORM
  • Participants: United Kingdom (Coordinator), Austria, Germany, Greece, Spain, France, Latvia, the Netherlands, Slovenia, Switzerland
  • Project N°: 668303
  • Total costs: € 18 467 697
  • EU contribution: € 17 997 665
  • Duration: January 2016 to December 2020

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details